ReShape Lifesciences Future Growth

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ReShape Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:RSLS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	8	-11	-14	-14	N/A
12/31/2023	9	-11	-17	-17	N/A
9/30/2023	10	-26	-17	-17	N/A
6/30/2023	10	-35	-20	-20	N/A
3/31/2023	11	-41	-20	-20	N/A
12/31/2022	11	-46	-22	-22	N/A
9/30/2022	11	-66	-23	-22	N/A
6/30/2022	12	-72	-25	-25	N/A
3/31/2022	13	-66	-21	-21	N/A
12/31/2021	14	-63	-16	-15	N/A
9/30/2021	14	-35	-14	-14	N/A
6/30/2021	14	-22	-7	-7	N/A
3/31/2021	12	-22	-8	-7	N/A
12/31/2020	11	-22	-9	-9	N/A
9/30/2020	12	-38	-8	-8	N/A
6/30/2020	12	-62	-12	-11	N/A
3/31/2020	15	-74	-12	-12	N/A
12/31/2019	15	-74	-14	-14	N/A
9/30/2019	11	-52	-20	-20	N/A
6/30/2019	8	-28	-20	-20	N/A
3/31/2019	4	-35	-24	-24	N/A
12/31/2018	1	-38	-28	-27	N/A
9/30/2018	0	-42	-29	-29	N/A
6/30/2018	1	-47	-30	-30	N/A
3/31/2018	1	-30	-30	-29	N/A
12/31/2017	1	-30	N/A	-25	N/A
9/30/2017	1	-29	N/A	-19	N/A
6/30/2017	1	-25	N/A	-18	N/A
3/31/2017	1	-23	N/A	-18	N/A
12/31/2016	1	-23	N/A	-21	N/A
9/30/2016	1	-26	N/A	-22	N/A
6/30/2016	1	-23	N/A	-24	N/A
3/31/2016	0	-26	N/A	-24	N/A
12/31/2015	0	-25	N/A	-23	N/A
9/30/2015	0	-25	N/A	-22	N/A
6/30/2015	0	-26	N/A	-20	N/A
3/31/2015	N/A	-27	N/A	-19	N/A
12/31/2014	N/A	-26	N/A	-19	N/A
9/30/2014	N/A	-27	N/A	-19	N/A
6/30/2014	N/A	-27	N/A	-19	N/A
3/31/2014	N/A	-26	N/A	-19	N/A
12/31/2013	N/A	-26	N/A	-18	N/A
9/30/2013	N/A	-26	N/A	-20	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RSLS's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if RSLS's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if RSLS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RSLS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if RSLS's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RSLS's Return on Equity is forecast to be high in 3 years time

ReShape Lifesciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

Consensus EPS estimates upgraded to US$16.50 loss

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Recent updates

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus EPS estimates upgraded to US$16.50 loss

Full year 2022 earnings: EPS misses analyst expectations

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Price target decreased to US$1.03

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Price target decreased to US$3.08

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape wins FDA clearance for device used in weight loss surgery

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$12.00

ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction.

ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN).

ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies